Daniel Friedman

Daniel Friedman is a Managing Director on BroadOak’s growth capital investing team where he specializes in portfolio management and investment execution. Prior to joining BroadOak in 2019, Daniel worked for Raymond James within the Life Sciences Investment Banking team where he focused on public financings and M&A for biotechnology and medical device companies.

Daniel currently serves as a director on the boards of PBS Biotech and Precision Cell Systems, as well as acting as an observer at Pluristyx and Biolog. Daniel previously acted as a board observer at Avidien Technologies and antibodies-online.